Analyst picks & changes

Company

Bank

Analyst

Coverage

Opinion

Wk chg

7/18 cls

Genfit S.A. (Euronext:GNFT)

Deutsche Bank

Alethia Young

New

Buy

23%

€29.50

Young initiated coverage with a €110 target on the potential of lead product GFT505. The dual peroxisome proliferation activated receptor (PPAR) alpha and delta agonist is in the Phase IIb GFT505-212-7 trial to treat non-alcoholic steatohepatitis (NASH), with data expected in 1Q15. Young projects peak sales of $9B for the product.

Kite Pharma Inc. (NASDAQ:KITE)

Cowen

Eric Schmidt

New

Outperform

-3%

$22.84